Shengnuo Biopharm completes U.S. FDA filing for constipation treatment API

Asian Tech Press (Nov 15) -- Chinese drugmaker Shengnuo Biopharm (688117.SH) announced Tuesday that it has completed the U.S. FDA filing for its linaclotide API in treating constipation.

Chengdu Shengnuo Biopharm Co., Ltd. said in a statement that it has recently completed its Drug Master File (DMF) filing with the U.S. Food and Drug Administration (FDA) for its linaclotide active pharmaceutical ingredient (API) product.

Linaclotide is a drug that has won FDA approval for marketing on August 30, 2012, and is mainly for the treatment of rritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC).

Related Topics

You must be login to post a comment.